Abstract
In this issue of Blood, Duployez et al present results from mutational profiling of >200 patients with core binding factor acute myeloid leukemia (CBF-AML). The identified mutational landscape is likely to have clinical relevance and hints at intriguing biological distinctions between these seemingly similar malignancies that will offer deep insights into the aberrant regulatory networks critical for leukemia development.
MeSH terms
-
Cell Cycle Proteins
-
Chromatin*
-
Chromosomal Proteins, Non-Histone
-
Cohesins
-
Core Binding Factors / genetics
-
Leukemia, Myeloid, Acute*
Substances
-
Cell Cycle Proteins
-
Chromatin
-
Chromosomal Proteins, Non-Histone
-
Core Binding Factors